Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases

Author:

Vladimirova L. Yu.1ORCID,Popova I. L.1ORCID,Abramova N. A.1ORCID,Teplyakova M. A.1ORCID,Tikhanovskaya N. M.1ORCID,Novoselova K. A.1ORCID,Lyanova A. A.1ORCID,Ryadinskaya L. A.1ORCID,Ezhova M. O.1,Myagkova V. S.1ORCID,Strakhova L. K.1ORCID

Affiliation:

1. National Medical Research Centre for Oncology

Abstract

Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients who are difficult to treat and have a short life expectancy. The possibilities of whole brain radiotherapy, stereotactic radiosurgery and surgery in such patients are rather limited. Trastuzumab emtansine (T-DM1) showed potential activity in this subset of patients. T-DM1 is an antibody-chemical conjugate (ADC) that delivers directly to HER2-positive cancer cells, thereby limiting damage to healthy tissue. At this point, the efficacy of trastuzumab emtansine has been demonstrated in several randomized trials as a second and subsequent lines of therapy for advanced breast cancer with a favorable toxicity profile of the drug. This article describes a clinical case of a patient with luminal B HER-2 positive breast cancer who, underwent stereotactic radiosurgery and was treated with trastuzumab emtansine as a the second line of treatment for disease progression with metastatic brain lesions after trastuzumab/pertuzumab-containing therapy. Partial regression of metastases with long-term duration of the effect was achieved treatment with trastuzumab emtazine has been being continued for 24 months. Tolerability of therapy was good: thrombocytopenia 2 degree was the main among side effects. The effect has been persisted for 2 years and the patient continues the treatment. Discussion of the results of real clinical practice with well-known studies was carried out.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference29 articles.

1. Ternovoy S.K., Abduraimov A.B., Kuchuk P.V. Diagnosis of cerebral metastases of breast cancer. Luchevaya diagnostika i terapiya = Diagnostic Radiology and Radiotherapy. 2011;(1):47–54. (In Russ.) Available at: https://elibrary.ru/item.asp?id=16395840.

2. Naskhletashvili D.R. Targeted therapy in breast cancer patients with HER-2 overexpression and brain metastases. Which treatment option has benefit? In: White Nights 2017: Collection of scientific papers of the III St Petersburg International Oncological Forum. St Petersburg, June 22–24, 2017. St Peterburg: Problems in oncology; 2017, pp. 232. (In Russ.) Available at: https://elibrary.ru/item.asp?id=30656752.

3. Banov S.M., Golanov A.V., Vetlova E.R., Ilyalov S.V., Osinov I.K., Kostyuchenko V.V. Results of radiosurgical treatment of patients with metastatic brain lesion. Voprosy onkologii = Problems in Oncology. 2017;63(1):52–61. (In Russ.) Available at: https://elibrary.ru/item.asp?id=28863234.

4. Poddubnaya I.V. Advances in modern chemotherapy. Sovremennaya onkologi­ ya = Journal of Modern Oncology. 2003;5(2):47–58. (In Russ.) Available at: https://modernonco.orscience.ru/1815-1434/article/view/26497.

5. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–2872. doi: 10.1200/JCO.2004.12.149.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3